Opinion|Videos|April 18, 2025
Future Directions for IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis Care
Panelists discuss how medical professionals anticipate new IL-17 inhibitor data, particularly from head-to-head trials like BE BOLD. Interest is growing in sonelokimab, an IL-17A/F nanobody (Papp, 2021). Further research is needed on long-term efficacy, safety, and optimal patient selection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What new data are you looking forward to seeing from the IL-17 inhibitor class in psoriasis?
- More head-to-head studies (BE BOLD)
- Sonelokimab—IL-17A/F nanobody (Papp, 2021)
- In your opinion, what research still needs to be done for this therapeutic class?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
2
KT-621 Produces 98% STAT6 Degradation in AD Patients
3
Site-Specific MED Variability Guides 308-nm Excimer Laser Dosing
4
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
5
